CMPX (Compass Therapeutics) Total Current Liabilities : $14.90 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Compass Therapeutics's total current liabilities for the quarter that ended in Mar. 2025 was $14.90

Compass Therapeutics Total Current Liabilities Historical Data

The historical data trend for Compass Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Therapeutics Total Current Liabilities Chart

Compass Therapeutics Annual Data

Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24

Total Current Liabilities

Get a 7-Day Free Trial 10.10 10.63 16.17 7.80 8.87

Compass Therapeutics Quarterly Data

Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25

Total Current Liabilities Get a 7-Day Free Trial 3.89 9.51 4.43 8.87 14.90

Compass Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Compass Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 5.743 + 0.338

+ Other Current Liabilities + Current Deferred Liabilities

= 2.793 + 0

= 8.87

Compass Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 13.299 + 0.109

+ Other Current Liabilities + Current Deferred Liabilities

= 1.492 + 0

= 14.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Compass Therapeutics Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Compass Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Total Current Liabilities

Comparable Companies

TRDA HRTX PHAT XOMA GOSS TVRD CADL OCGN CRVS TSVT VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 601, Boston, MA, USA, 02135

Website

https://www.compasstherapeutics.com

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Executives

Thomas J. Schuetz director, officer: Chief Executive Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063

Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Richard S Lindahl director NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191

David M Wurzer director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511

Vered Bisker-leib officer: Chief Operating Officer C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142

James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025

Ellen Chiniara director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453

Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023

Philip Ferneau director 10 ALLEN STREET, HANOVER NH 03755

Orbimed Capital Gp V Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Susan Kalled officer: Chief Scientific Officer COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135

Brett Kaplan director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016

Compass Therapeutics Headlines

From GuruFocus

Compass Therapeutics (CMPX) Achieves Promising Results in BTC Treatment Study
By GuruFocus News • 04-01-2025

Insider Buying: Thomas Schuetz Acquires Additional Shares of Compass Therapeutics Inc (CMPX)
By GuruFocus News • 05-27-2025

TANG CAPITAL MANAGEMENT LLC Increases Stake in Compass Therapeutics Inc
By GuruFocus News • 01-17-2025

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
By Marketwired • 03-31-2025

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
By Marketwired • 04-28-2025

Compass Therapeutics Appoints Biopharmaceutical Industry Leader�Barry Shin as Chief Financial Officer
By Marketwired • 12-10-2024

Janus Henderson Group PLC's Strategic Reduction in Compass Therapeutics Inc Holdings
By GuruFocus News • 11-14-2024

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
By Marketwired • 11-12-2024

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
By Marketwired • 11-08-2024

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
By Marketwired • 12-02-2024

Compass Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Liabilities	Get a 7-Day Free Trial															3.89	9.51	4.43	8.87	14.90

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	5.743	+	0.338
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	2.793	+	0
	=	8.87

Thomas J. Schuetz	director, officer: Chief Executive Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard S Lindahl	director	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
David M Wurzer	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib	officer: Chief Operating Officer	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau	director	10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled	officer: Chief Scientific Officer	COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016